Colorado Medicaid now covers vitiligo treatment
The Colorado Drug Utilization Review Board agreed with the AADA and classified vitiligo as a medical condition.
Precedent exists for treating vitiligo as a medical condition. In 2022, the FDA approved topical ruxolitinib for regimentation of non-segmental vitiligo in patients ages 12 or older.
As a result of the AADA’s advocacy, the Colorado Medicaid program began covering topical ruxolitinib (Opzelura) for nonsegmental vitiligo on July 1.
